South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharmaceuticals for the export of its gastroesophageal reflux disease drug K-CAB tablet (ingredient name Tegoprazan) in the Middle East and North Africa (MENA) region.
South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respective blockbuster drugs Kanarb and K-CAB in January next year. This deal is the first collaboration between domestic pharmaceutical companies
South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophageal reflux disease (GERD) drug K-CAB.K-CAB, expected to exceed 100 billion won ($76.2 million) in sales this year, is a blockbuster drug for HK in
South Korean bio-health company HK inno.N announced on Monday that it has released the new drug K-CAB for gastroesophageal reflux disease (GERD) in Singapore and held a commemorative symposium for local medical professionals. With this launch, K-CAB has now been introduced in Singapore, follow
HK inno.N's K-CAB South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, will receive insurance coverage in China.According to industry sources on Thursday, K-CAB Tab was included in the National Reimbu
HK inno.N scientist at a lab in Hanam, Gyeonggi Province HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company announced Thursday it received the sales permit from China’s National Medical Products